Description
Ziprasidone is an atypical antipsychotic that acts as an antagonist at D2 receptors and 5-HT1D receptors and as an agonist at 5-HT1A receptors; this binding profile allows it to exhibit antipsychotic, antidepressant, and anxiolytic benefits. Ziprasidone is clinically used to treat bipolar disorder, schizophrenia, and sleeplessness/insomnia in individuals with psychosis. In a clinical setting, ziprasidone improved latency to REM, duration of slow wave sleep, total sleep time, and sleep efficiency.
References
Takeuchi H, Suzuki T, Bies RR, et al. Estimated dopamine D2 receptor occupancy from plasma concentrations of atypical antipsychotics and subjective experience/drug attitude in schizophrenia: an analysis of the CATIE data. Schizophr Res. 2013 Nov;150(2-3):373-9. PMID: 24028745.
Findling RL, Cavuş I, Pappadopulos E, et al. Efficacy, long-term safety, and tolerability of ziprasidone in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol. 2013 Oct;23(8):545-57. PMID: 24111980.
Baskaran A, Summers D, Willing SL, et al. Sleep architecture in ziprasidone-treated bipolar depression: a pilot study. Ther Adv Psychopharmacol. 2013 Jun;3(3):139-49. PMID: 24167686.
Farah A. Atypicality of atypical antipsychotics. Prim Care Companion J Clin Psychiatry. 2005;7(6):268-74. PMID: 16498489.
Stimmel GL, Gutierrez MA, Lee V. Ziprasidone: an atypical antipsychotic drug for the treatment of schizophrenia. Clin Ther. 2002 Jan;24(1):21-37. PMID: 11833834.
